Guizhou University School of Medicine, Guizhou, 550025, PR China.
State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, PR China.
Exp Cell Res. 2020 Oct 1;395(1):112188. doi: 10.1016/j.yexcr.2020.112188. Epub 2020 Jul 21.
Esophageal squamous cell carcinoma (ESCC) has high aggressiveness and poor prognosis, and is the major histological subtype of esophageal cancer in East Asia and East Africa. In this study, we found that USP46, a deubiquitinating enzyme, is overexpressed in clinical ESCC samples, especially in patients with positive lymph node metastasis. Moreover, USP46 enhances the migration and invasion of ESCC cells by mediating the EMT process in vitro, and promotes lymph nodes and lung metastasis of ESCC in vivo. In addition, we found that USP46 is a bona fide deubiquitinating enzyme to stabilize the protein level of ENO1 through deubiquitination. ENO1 protein level was also positively correlated with USP46 in the ESCC samples. In summary, these findings reveal the functional role of USP46 as a deubiquitinating enzyme on ESCC metastasis, providing us a potential therapeutic target for the treatment of ESCC.
食管鳞状细胞癌(ESCC)侵袭性强、预后差,是东亚和东非地区食管癌的主要组织学亚型。在本研究中,我们发现去泛素化酶 USP46 在临床 ESCC 样本中高表达,尤其是在有阳性淋巴结转移的患者中。此外,USP46 通过介导 EMT 过程在体外增强 ESCC 细胞的迁移和侵袭,并在体内促进 ESCC 的淋巴结和肺转移。此外,我们发现 USP46 是一种真正的去泛素化酶,通过去泛素化稳定 ENO1 蛋白水平。ENO1 蛋白水平在 ESCC 样本中也与 USP46 呈正相关。综上所述,这些发现揭示了 USP46 作为去泛素化酶在 ESCC 转移中的功能作用,为 ESCC 的治疗提供了一个潜在的治疗靶点。